{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:38:18Z","timestamp":1768808298574,"version":"3.49.0"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0235213","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T17:32:10Z","timestamp":1593019930000},"page":"e0235213","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5518-1078","authenticated-orcid":true,"given":"Arisa","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Maruyama-Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2940-9734","authenticated-orcid":true,"given":"Shimpei","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"pone.0235213.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"LA Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"pone.0235213.ref002","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archopht.1997.01100150480005","article-title":"The Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy","volume":"115","author":"LA Yannuzzi","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"pone.0235213.ref003","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: Evidence-Based Guidelines for Clinical Diagnosis and Treatment","volume":"33","author":"AHC Koh","year":"2013","journal-title":"Retina"},{"key":"pone.0235213.ref004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese Patients","volume":"144","author":"I Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0235213.ref005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","article-title":"One-Year Outcomes of Photodynamic Therapy in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese Patients","volume":"115","author":"F Gomi","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0235213.ref006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000221837","article-title":"Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A multicenter study in hyogo prefecture, japan","volume":"223","author":"S Honda","year":"2009","journal-title":"Ophthalmologica"},{"issue":"8","key":"pone.0235213.ref007","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","article-title":"Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series","volume":"111","author":"WM Chan","year":"2004","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0235213.ref008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajo.2011.12.019","article-title":"One-Year Results of Three Monthly Ranibizumab Injections and As-Needed Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients","volume":"154","author":"T Hikichi","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"pone.0235213.ref009","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","article-title":"Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results","volume":"156","author":"A Oishi","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0235213.ref010","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/IAE.0000000000001818","article-title":"Intravitreal injection of aflibercept in patients with polypoidal choroidal vasculopathy a 3-year follow-up","volume":"38","author":"M Maruyama-Inoue","year":"2018","journal-title":"Retina"},{"issue":"1","key":"pone.0235213.ref011","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"F Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"pone.0235213.ref012","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"92","author":"TYY Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"pone.0235213.ref013","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","article-title":"Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response","volume":"98","author":"K Hatz","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"pone.0235213.ref014","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/IAE.0000000000000933","article-title":"Aflibercept for polypoidal choroidal vasculopathy","volume":"36","author":"M Inoue","year":"2016","journal-title":"Retina"},{"issue":"11","key":"pone.0235213.ref015","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial","volume":"135","author":"A Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"pone.0235213.ref016","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1007\/s00417-013-2323-6","article-title":"Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy","volume":"251","author":"M Saito","year":"2013","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"9","key":"pone.0235213.ref017","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1089\/jop.2013.0044","article-title":"Two-Year results of photodynamic therapy with or without intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy","volume":"29","author":"Y Sakurada","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"pone.0235213.ref018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10384-016-0479-4","article-title":"Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab","volume":"61","author":"W Kikushima","year":"2017","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"pone.0235213.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0176100","article-title":"Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study","volume":"12","author":"K Takayama","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"pone.0235213.ref020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-016-3500-1","article-title":"One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy","volume":"255","author":"W Matsumiya","year":"2017","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"1","key":"pone.0235213.ref021","first-page":"1","article-title":"Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy","volume":"7","author":"W Kikushima","year":"2017"},{"key":"pone.0235213.ref022","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials","volume":"117","author":"Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"pone.0235213.ref023","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ajo.2010.10.030","article-title":"Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy","volume":"151","author":"I Maruko","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"pone.0235213.ref024","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/bjophthalmol-2015-308074","article-title":"Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: A comparative study","volume":"100","author":"JH Kim","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"pone.0235213.ref025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000501724","article-title":"Long-Term Incidence and Growth of Chorioretinal Atrophy in Patients with Polypoidal Choroidal Vasculopathy","volume":"243","author":"EY Choi","year":"2020","journal-title":"Ophthalmologica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T17:32:29Z","timestamp":1593019949000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0235213"}},"subtitle":[],"editor":[{"given":"Demetrios G.","family":"Vavvas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0235213","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}